In Vitro Antibacterial Activity of Sulbactam-Durlobactam and Eravacycline Against Carbapenem-Resistant Acinetobacter baumannii in China and Analysis of Sulbactam-Durlobactam Resistance Mechanisms
Polish Journal of Microbiology · 01.06.2026 · 75 (2) · 210-219
DOI: 10.33073/pjm-2026-019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Polish Journal of Microbiology, online erschienen am 30.06.2026. Verfasst von Xuelian He und 5 weiteren Autor:innen. Beteiligte Einrichtung: 1Beijing Friendship Hospital, Capital Medical University, Beijing China. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Sulbactam, Anti-Bacterial Agents, Carbapenems. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The management of carbapenem-resistant Acinetobacter baumannii (CRAB) infections remains a formidable clinical challenge. This study evaluated the in vitro antimicrobial activities of sulbactam-durlobactam (SUL-DUR) and eravacycline (ERV) against CRAB isolates and elucidated the genomic landscapes of resistance and virulence determinants in SUL-DUR-resistant strains to inform therapeutic decision-making. A total of 233 clinical CRAB isolates were collected and screened for susceptibility to SUL-DUR and ERV using the Kirby-Bauer (K-B) disk diffusion assay. Isolates exhibiting resistance to SUL-DUR were further characterized via metagenomic next-generation sequencing (mNGS) to identify key resistance and virulence factors. SUL-DUR and ERV demonstrated robust in vitro activity, with susceptibility rates of 92.3% and 91.4%, respectively. Notably, no isolates exhibited concurrent non-susceptibility to both agents. Genomic analysis of 14 SUL-DUR-resistant strains revealed a complex and heterogeneous distribution of genetic determinants. The presence of bla NDM-1 was identified as a critical driver of SUL-DUR resistance. Additionally, reduced susceptibility was potentially associated with specific mutations in bla OXA-23 , bla OXA-66 , and bla TEM-1 , while hyperactive efflux systems and altered membrane permeability further synergized to enhance the resistance phenotype. Despite the extensive-drug-resistant (XDR) nature of current CRAB isolates, they maintain high sensitivity to SUL-DUR and ERV. Our findings underscore that SUL-DUR and ERV represent highly promising therapeutic options with significant development potential and broad clinical application prospects for the management of CRAB-related infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 1Beijing Friendship Hospital, Capital Medical University, Beijing China.
- 2Beijing Chest Hospital, Capital Medical University, Beijing China.
Zitieren
APA
He, X., Ma, S., Zhou, Y., Wei, J., Zhuo, Z., & Ma, L. (2026). In Vitro Antibacterial Activity of Sulbactam-Durlobactam and Eravacycline Against Carbapenem-Resistant Acinetobacter baumannii in China and Analysis of Sulbactam-Durlobactam Resistance Mechanisms. Polish Journal of Microbiology, 75(2), 210-219. https://doi.org/10.33073/pjm-2026-019
Vancouver
He X, Ma S, Zhou Y, Wei J, Zhuo Z, Ma L. In Vitro Antibacterial Activity of Sulbactam-Durlobactam and Eravacycline Against Carbapenem-Resistant Acinetobacter baumannii in China and Analysis of Sulbactam-Durlobactam Resistance Mechanisms. Polish Journal of Microbiology. 2026;75(2):210-219. doi:10.33073/pjm-2026-019
BibTeX
@article{He2026,
author = {He, Xuelian and Ma, Shang and Zhou, Yanyan and Wei, Jingjuan and Zhuo, Zhongling and Ma, Liyan},
title = {In Vitro Antibacterial Activity of Sulbactam-Durlobactam and Eravacycline Against Carbapenem-Resistant Acinetobacter baumannii in China and Analysis of Sulbactam-Durlobactam Resistance Mechanisms},
journal = {Polish Journal of Microbiology},
year = {2026},
volume = {75},
number = {2},
pages = {210--219},
doi = {10.33073/pjm-2026-019}
}
EUVIMED